source
- LEO Pharma spends $435 million to acquire rare-disease skin drug dersimelagonLEO Pharma announced it will pay $435 million to buy the rights to dersimelagon, an oral MC1R agonist originally developed by Tanabe Pharma. The drug has completed Phase 3 trials for two rare phot…
- GenBio AI launches AIDO Cell, a virtual model that simulates whole-cell behaviorGenBio AI, a Palo Alto startup, unveiled AIDO Cell, a virtual cell platform that lets researchers view a cell’s interior like a map. The system visualizes proteins, RNA and DNA and can simulate gen…